27Aug 2023
USFDA Nod To Gilead Sciences Veklury To Treat covlD19 In People With Mild To Severe Hepatic Impairment With No Dose Adjustment

USFDA Nod To Gilead Sciences Veklury To Treat covlD19 In People With Mild To Severe Hepatic Impairment With No Dose Adjustment

Gilead's Veklury (remdesivir) gains FDA approval for COVID-19 treatment in individuals with liver disease. The supplemental application covers mild to severe hepatic impairment, extending Veklury's antiviral scope. This marks a milestone as the sole approved COVID-19 antiviral for all liver disease stages. The decision is based on a Phase I study indicating safe pharmacokinetics in hepatic impairment patients without new safety concerns. Despite recommendations for initial hepatic testing, no dose adjustments are now necessary.

  • #family health

Like

Save

Share